Gilead acquired Kite Pharma in October 2017 for $11.9 billion. Read about our life science construction project Kite TCF05 (Frederick, MD) in ABC of Metro Washington Chapter. Kite Pharma, a subsidiary of Gilead Sciences, is constructing the new 279,000-square-foot plant in Urbana, after purchasing the property in November 2018. MAINZ, Germany & SANTA MONICA, Calif.- (BUSINESS WIRE)- BioNTech SE (Nasdaq: BNTX, BioNTech) and Kite, a Gilead Company (Nasdaq: GILD, Kite) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg, MD, from Kite. Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor. The Maryland site will support the work of a new Cooperative Research and Development Agreement with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Kite has also leased a 26,000-square-foot facility in Gaithersburg, Maryland. In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma that will be used for cell-therapy research, development, and the expansion of clinical manufacturing capabilities. Kite Announces Completion of Marketing Authorization Transfer for Yescarta CAR T-cell Therapy in Japan June 06, 2023. The new facility is scheduled to be fully operational in 2020. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the. The facility will engineer and produce cell therapies, including axicabtagene ciloleucel, a chimeric antigen receptor T cell therapy that is currently under review by the European Medicines Agency and which was approved in October 2017 in the US as Yescarta for treating adult patients with relapsed or refractory large B-cell lymphoma. Kite Pharma - Developer of cancer immunotherapy products using genetic engineering. 20Kite Pharma's Urbana cell therapy manufacturing facility has received federal approval for commercial production of its treatment for blood cancer, the global biopharmaceutical company. Significant legal events involving law firms. The 117,000-square-foot site will be used to manufacture and deliver cell therapies to people living with cancer in Europe. Daily and real-time news and case alerts on organizations, industries, and customized search queries. Kite has leased a new facility in Hoofddorp, the Netherlands to engineer cell therapies. Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, has leased and purchased new facilities in the US and Europe to expand its cell-therapy manufacturing capabilities.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |